WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

Previous ATC codeATC level nameNew ATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
L01XY02pertuzumab and trastuzumabL01FY0101.09.20232024
L01XY03nivolumab and relatlimabL01FY0201.09.20232024
L04AA02muromonab-CD3L04AG01Final2024
L04AA10sirolimusL04AH01Final2024
L04AA13leflunomideL04AK01Final2024
L04AA18everolimusL04AH02Final2024
L04AA21efalizumabL04AG02Final2024
L04AA23natalizumabL04AG03Final2024
L04AA25eculizumabL04AJ01Final2024
L04AA26belimumabL04AG04Final2024
L04AA27fingolimodL04AE01Final2024
L04AA29tofacitinibL04AF01Final2024
L04AA31teriflunomideL04AK02Final2024
L04AA33vedolizumabL04AG05Final2024
L04AA34alemtuzumabL04AG06Final2024
L04AA35begelomabL04AG07Final2024
L04AA36ocrelizumabL04AG08Final2024
L04AA37baricitinibL04AF02Final2024
L04AA38ozanimodL04AE02Final2024
L04AA39emapalumabL04AG09Final2024
L04AA42siponimodL04AE03Final2024
L04AA43ravulizumab L04AJ02Final2024
L04AA44upadacitinibL04AF03Final2024
L04AA45filgotinibL04AF04Final2024
L04AA46itacitinibL04AF05Final2024
L04AA47inebilizumabL04AG10Final2024
L04AA49peficitinibL04AF06Final2024
L04AA50ponesimodL04AE04Final2024
L04AA51anifrolumabL04AG11Final2024
L04AA52ofatumumabL04AG12Final2024
L04AA53teprotumumabL04AG13Final2024
L04AA54pegcetacoplanL04AJ03Final2024
L04AA55sutimlimabL04AJ04Final2024
L04AA56deucravacitinibL04AF07Final2024
L04AA57ublituximabL04AG14Final2024
L04AA59avacopanL04AJ05Final2024
N05CM19suvorexantN05CJ01 Final2024
N05CM21lemborexantN05CJ02 Final2024

Last updated: 2023-05-11